1-[bis(4-fluorophenyl)methoxy]-4-chlorobutane | 173186-93-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[bis(4-fluorophenyl)methoxy]-4-chlorobutane
• 英文别名: 1-[4,4'-difluorodiphenylmethoxy]-4-chlorobutane；1-[4-chlorobutoxy-(4-fluorophenyl)methyl]-4-fluorobenzene
• CAS: 173186-93-1
• 化学式: C₁₇H₁₇ClF₂O
• 分子量: 310.771
• InChiKey: VQSPRFSTGQANGE-UHFFFAOYSA-N

物化性质

• 沸点：
  371.5±42.0 °C(Predicted)
• 密度：
  1.187±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[bis(4-fluorophenyl)methoxy]-4-chlorobutane 在 potassium iodide potassium carbonate 、 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 、 二氯甲烷 为溶剂， 反应 76.5h， 生成 1-Benzoyl-4-[1-[bis(4-fluorophenyl)methoxy]-4-butyl]piperazine
  参考文献：
  名称：

  [EN] DIAGNOSTIC AND THERAPEUTIC ALKYL PIPERIDINE/PIPERAZINE COMPOUNDS AND PROCESS
  [FR] COMPOSES PIPERIDINE/PIPERAZINE ALKYLE THERAPEUTIQUES ET DIAGNOSTIQUES ET PROCESSUS

  摘要：

  公开号：

  WO2004063150A3
• 作为产物：
  描述：

  5-fluoro-2-(4-fluorobenzyl)phenol 、 三氯叔丁醇 在 PTSA 作用下， 以 水 、 苯 为溶剂， 以96%的产率得到1-[bis(4-fluorophenyl)methoxy]-4-chlorobutane
  参考文献：
  名称：

  N-(benzhydryloxyalkyl)-4-(carboxy/carbamoyl methyl)-piperidine

  摘要：

  本发明涉及通式（I）的取代氮杂环衍生物，其为外消旋或光学纯形式和/或顺反异构体形式，其药学上可接受的盐，并用于制备具有心理活性，特别是抗抑郁活性的药物。

  公开号：

  US05846980A1

文献信息

• Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process
  申请人：Elmaleh R. David

  公开号：US20050222166A1

  公开（公告）日：2005-10-06

  Piperidine or piperazine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided. The compounds are characterized by the formulae: wherein: n is an integer of 1 to 6; X, Y, Z 1 and Z 2 can be the same or different and are hydrogen, halo, haloalkyl, alkyl, aryl, (C 1 -C 6 ) alkoxy, N-alkyl,(C 2 -C 6 ) acyloxy, N-alkylene, —SH, —SR, wherein R is from the same group as R 1 and R 2 and can be the same or different than R 1 and R 2 , amino, nitro, cyano, hydroxy, C(═O) OR 6 , —C(═O) NR 5 R 4 , NR 3 R 2 , or S(αO) k R 1 wherein k is 1 or 2, and R 1 to R 6 are independently hydrogen or (C 1 -C 6 ) alkyl; R 1 , and R 2 can be the same or different and are hydrogen, (C 1 -C 6 ) alkyl, hydroxyalkyl or mercaptoalkyl, —C(═O) OR 1 , cyano, (C 1 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, or 1,2,4-oxadiazol-5-yl optionally substituted at the 3-position by Z 4 wherein any (C 1 -C 6 ) alky, (C 1 -C 6 ) alkanoyl, (C 2 -C 6 ) alkenyl or (C 2 -C 6 ) alkynyl can optionally be substituted by 1, 2 or 3 Z; R 7 can be hydrogen, O or phenyl R 8 can be hydrogen, phenyl, halophenyl, nitrophenyl, pyridyl, piperonyl or sulfoxonitrophenyl Z 4 is (C 1 -C 6 ) alkyl or phenyl, optionally substituted by 1, 2 or 3 Z 1 W is O or S T is amino or C 1 -C 6 aminoalkyl A is N or C T is C 1 -C 6 alklyl or sulfonyl and V is alkyl (C 0 -C 6 ), alkenyl, alkynyl, haloaryl, alkyl phenol, alkyl halophenyl, and R 1 or R 2 as indicated above and φ is phenyl, naphthyl, thienyl or pyridinyl.

  提供用于治疗由多巴胺神经元活动缺乏特征的神经退行性疾病或用于成像多巴胺神经元的哌啶或哌嗪化合物。这些化合物的特征是由以下公式确定：其中：n为1至6的整数；X、Y、Z1和Z2可以相同也可以不同，是氢、卤素、卤代烷基、烷基、芳基、（C1-C6）烷氧基、N-烷基、（C2-C6）酰氧基、N-烷基烯、—SH、—SR，其中R与R1和R2相同且可以与R1和R2不同，氨基、硝基、氰基、羟基、C(═O)OR6、—C(═O)NR5R4、NR3R2或S(αO)kR1，其中k为1或2，R1至R6独立地为氢或（C1-C6）烷基；R1和R2可以相同也可以不同，是氢、（C1-C6）烷基、羟基烷基或巯基烷基、—C(═O)OR1、氰基、（C1-C6）烯基、（C2-C6）炔基或1,2,4-噁二唑-5-基，在3-位可选择地由Z4取代，其中任何（C1-C6）烷基、（C1-C6）酰基、（C2-C6）烯基或（C2-C6）炔基可选择地由1、2或3个Z取代；R7可以是氢、氧或苯基；R8可以是氢、苯基、卤苯基、硝基苯基、吡啶基、哌罗基或磺氧硝基苯基；Z4是（C1-C6）烷基或苯基，可选择地由1、2或3个Z取代；W是氧或硫；T是氨基或C1-C6氨基烷基；A是N或C；T是C1-C6烷基或磺酰基；V是烷基（C0-C6）、烯基、炔基、卤代芳基、烷基酚、烷基卤苯基，以及如上所示的R1或R2；φ是苯基、萘基、噻吩基或吡啉基。
• Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process
  申请人：Elmaleh David R.

  公开号：US20120208847A1

  公开（公告）日：2012-08-16

  Described herein are piperidine and piperazine compounds useful for treating neurodegenerated diseases characterized by a lack of dopamine neuron activity. The compounds are also useful for imaging dopamine neurons.

  本文描述了对于治疗神经退行性疾病的哌啶和哌嗪类化合物，这些疾病特征是缺乏多巴胺神经元活动。这些化合物还可用于成像多巴胺神经元。
• New N-(benzhydryloxyalkyl)-4-(carboxy/carbamoylmethyl) piperidine derivatives with antidepressant activity
  作者：Y El Ahmad、P Maillet、E Laurent、A Talab、JF Teste、MJ Cédat、PY Fiez-Vandal、R Dokhan、R Ollivier

  DOI：10.1016/s0223-5234(97)83972-4

  日期：1997.1

  Several benzhydryloxylalkylpiperidine derivatives were prepared with the aim of obtaining new antidepressant compounds. The influence of the length of the aliphatic chain and of aromatic and piperidine ring substitutions was studied. The pharmacological activity of compounds was investigated in vivo by means of a screening comprising four pharmacological tests: antagonism of reserpine and apomorphine hypothermia; increase of yohimbine induced mortality; and antagonism of immobility in tail suspension test. An in-depth pharmacological study was performed with the more active compounds and a binding study to serotonin (5-HT), norepinephrine (NE) and dopamine (DA) reuptake sites was performed for the preferred compounds. The most active compounds [+], [-]-cis-31, 32 and 46 exhibited an interesting psychopharmacological profile after intraperitoneal administration. This profile was confirmed by the oral route for 31 and 46. In vitro, these compounds showed a non-selective inhibition of DA, NE and 5-HT uptake.
• Novel (bisarylmethoxy)butylpiperidine analogues as neurotransmitter transporter inhibitors with activity at dopamine receptor sites
  作者：Sung-Woon Choi、David R. Elmaleh、Robert N. Hanson、Timothy M. Shoup、Alan J. Fischman

  DOI：10.1016/s0968-0896(02)00348-6

  日期：2002.12

  A series of (bisarylmethoxy)butylpiperidine derivatives was prepared and evaluated in vitro and in vivo to determine the structural requirements necessary for dual activity at the DAT and DA/5-HT receptor sites, These hybrid ligands, constructed by combining pharmacophores specific for the DAT and DA/5-HT receptors, could be useful drugs for treating cocaine addiction by assisting cocaine addicts in maintaining abstinence. The series was evaluated in vitro for DAT and DA/5-HT receptor activity and then selected compounds were tested in vivo for their effects on cocaine-induced hyperlocomotor activity (LMA). The majority of the new compounds demonstrated high to moderate affinity (4-191 nM) for the DAT with 4-hydroxy-4-phenylpiperidine analogues 14 and 15 possessing the greatest affinity. Compounds 15 and 22 exhibited the highest ratio of reuptake inhibition-to-binding (discrimination ratio, DR), 111 and 323, respectively. These derivatives had modest affinity and antagonistic activity for dopamine D-2/D-3 receptors. Compounds 9 and 15 (DR = 0.9 and 111. respectively) stimulated locomotor activity, whereas the other compounds suppressed this response, All compounds tested except for 17 and 21 attenuated cocaine-induced hyperlocomotion. (C) 2002 Elsevier Science Ltd. All rights reserved.
• DERIVES DE N-(BENZHYDRYLOXYALKYL)-4-(CARBOXY/CARBAMOYL-METHYL)-PIPERIDINE COMME AGENTS ANTIDEPRESSIFS
  申请人：COOPERATION PHARMACEUTIQUE FRANCAISE

  公开号：EP0751937A1

  公开（公告）日：1997-01-08